HUTCHMED (LON:HCM) Trading 9% Higher – Still a Buy?

Shares of HUTCHMED (China) Limited (LON:HCM) traded up 9% during mid-day trading on Thursday . The company traded as high as GBX 184 and last traded at GBX 175. 158,530 shares were traded during mid-day trading, an increase of 306% from the average daily volume of 39,056 shares. The stock had previously closed at GBX 160.50.

HUTCHMED Trading Up 9.0%

The company has a current ratio of 4.96, a quick ratio of 2.97 and a debt-to-equity ratio of 7.91. The stock has a 50-day simple moving average of GBX 177.74 and a 200 day simple moving average of GBX 201.21. The company has a market cap of £1.50 billion, a price-to-earnings ratio of 3.30 and a beta of 0.37.

About HUTCHMED

We are among the first global-focused novel drug discovery companies in China. Over the past two decades, we have established a fully integrated R&D platform with world-class discovery and development capabilities. Since inception, we have focused on bringing cancer drug candidates from in-house discovery to patients around the world, with our first three oncology medicines now approved marketed in China, the first of which is also marketed in the U.S.

We have also developed a profitable commercial platform with deep pan-China market access, which manufactures, markets and distributes our novel oncology products, as well as prescription drugs and consumer health products in China.

HUTCHMED is listed on the Nasdaq Global Select Market, the Stock Exchange of Hong Kong Limited and the London Stock Exchange’s AIM market (Nasdaq/AIM:HCM; HKEX:13).